P1/2, N=3, Terminated, Hoffmann-La Roche | N=150 --> 3 | Trial completion date: Jan 2027 --> Mar 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2027 --> Mar 2024; Sponsor decision (not related to safety, efficacy or quality).

17 days ago

Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases

MUC16 (Mucin 16, Cell Surface Associated) • HLA-G (Major Histocompatibility Complex, Class I, G)

HLA-G positive

Actemra IV (tocilizumab) • RG6353

3ms

Study of RO7515629 in Participants With HLA-G Positive Solid Tumors (clinicaltrials.gov)

P1/2, N=150, Active, not recruiting, Hoffmann-La Roche | Recruiting --> Active, not recruiting

3 months ago

Enrollment closed

MUC16 (Mucin 16, Cell Surface Associated) • HLA-G (Major Histocompatibility Complex, Class I, G)

HLA-G positive

Actemra IV (tocilizumab) • RG6353

1year

Study of RO7515629 in Participants With HLA-G Positive Solid Tumors (clinicaltrials.gov)

P1/2, N=150, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting

1 year ago

Enrollment open • Metastases

MUC16 (Mucin 16, Cell Surface Associated) • HLA-G (Major Histocompatibility Complex, Class I, G)

HLA-G positive

Actemra IV (tocilizumab) • RG6353